Huntington's Disease
Conditions
Keywords
Premanifest, At-Risk, Huntington's Disease, HD
Brief summary
The purpose of this clinical trial is to extend the Pre-Crest study (Protocol # (NCT00592995) to further assess the long-term safety and tolerability of up to 30 grams daily creatine in individuals at-risk for Huntington's Disease (HD) and to assess whether biomarkers responsive to creatine in symptomatic individuals are informative in premanifest individuals over a longer duration.
Detailed description
Extensive evidence exists that neurodegeneration begins many years before HD can be diagnosed clinically. Therefore, it is most desirable to begin a neuroprotective therapy before or during this premanifest period with the aim of delaying onset, as well as slowing functional decline. Cellular energy depletion is present early in HD and can be ameliorated by creatine, which helps regenerate cellular ATP. Preclinical evidence for creatine's potential neuroprotective effects in animal models of HD has been well-documented. Before the clinical efficacy of creatine can be tested in premanifest HD, its long-term safety and tolerability must be assessed in these individuals and its ability to favorably modify biomarkers of HD should also be confirmed. This extension trial will continue to follow eligible individuals who completed the PreCREST study on open-label creatine (up to 30 grams daily) for long term safety and tolerability. Additional biological and imaging biomarkers of disease progression and potential response to treatment will also be assessed.
Interventions
DRUGCreatine Monohydrate
Up to 30 grams daily creatine monohydrate
Sponsors
National Institutes of Health (NIH)
Massachusetts General Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
26 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Individuals who have completed the Pre-CREST Study. * Individuals capable of providing independent informed consent and complying with trial procedures.
Exclusion criteria
-Clinical evidence of unstable medical or psychiatric illness in the investigator's judgment. Additional eligibility criteria apply.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety | 12 months | Frequency of adverse events |
| Tolerability | 12 months | Proportion of subjects completing the extension study at given dose level |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical measures | 12 months | Components of the UHDRS (United Huntington's Disease Rating Scale) |
| Biological Markers of Disease Progression | 12 Months | Biological indicators that creatine treatment might affect the progression of HD: plasma levels of creatine, serum levels of 8OH2'dG and 8OHG, magnetic resonance imaging (MRI), morphometric neuroimaging (biomarker of neurodegeneration), metabolomic profiling, and gene expression analysis to assess transcriptional effects of HD and creatine therapy. |
Countries
United States
Outcome results
None listed